227 related articles for article (PubMed ID: 37509122)
1. Quantitative, Targeted Analysis of Gut Microbiota Derived Metabolites Provides Novel Biomarkers of Early Diabetic Kidney Disease in Type 2 Diabetes Mellitus Patients.
Balint L; Socaciu C; Socaciu AI; Vlad A; Gadalean F; Bob F; Milas O; Cretu OM; Suteanu-Simulescu A; Glavan M; Ienciu S; Mogos M; Jianu DC; Petrica L
Biomolecules; 2023 Jul; 13(7):. PubMed ID: 37509122
[TBL] [Abstract][Full Text] [Related]
2. Metabolite Profiling of the Gut-Renal-Cerebral Axis Reveals a Particular Pattern in Early Diabetic Kidney Disease in T2DM Patients.
Balint L; Socaciu C; Socaciu AI; Vlad A; Gadalean F; Bob F; Milas O; Cretu OM; Suteanu-Simulescu A; Glavan M; Ienciu S; Mogos M; Jianu DC; Petrica L
Int J Mol Sci; 2023 Mar; 24(7):. PubMed ID: 37047187
[TBL] [Abstract][Full Text] [Related]
3. Metabolites Potentially Derived from Gut Microbiota Associated with Podocyte, Proximal Tubule, and Renal and Cerebrovascular Endothelial Damage in Early Diabetic Kidney Disease in T2DM Patients.
Balint L; Socaciu C; Socaciu AI; Vlad A; Gadalean F; Bob F; Milas O; Cretu OM; Suteanu-Simulescu A; Glavan M; Ienciu S; Mogos M; Jianu DC; Ursoniu S; Dumitrascu V; Vlad D; Popescu R; Petrica L
Metabolites; 2023 Jul; 13(8):. PubMed ID: 37623837
[TBL] [Abstract][Full Text] [Related]
4. Serum metabolomics detected by LDI-TOF-MS can be used to distinguish between diabetic patients with and without diabetic kidney disease.
Qian F; Zhao L; Zhang D; Yu M; Zhou W; Jin J
FEBS Open Bio; 2023 Oct; 13(10):1844-1858. PubMed ID: 37525631
[TBL] [Abstract][Full Text] [Related]
5. Urine metabolomics reveals biomarkers and the underlying pathogenesis of diabetic kidney disease.
Luo M; Zhang Z; Lu Y; Feng W; Wu H; Fan L; Guan B; Dai Y; Tang D; Dong X; Yun C; Hocher B; Liu H; Li Q; Yin L
Int Urol Nephrol; 2023 Apr; 55(4):1001-1013. PubMed ID: 36255506
[TBL] [Abstract][Full Text] [Related]
6. LC-MS-based metabolomics analysis to identify meprin-β-associated changes in kidney tissue from mice with STZ-induced type 1 diabetes and diabetic kidney injury.
Gooding J; Cao L; Ahmed F; Mwiza JM; Fernander M; Whitaker C; Acuff Z; McRitchie S; Sumner S; Ongeri EM
Am J Physiol Renal Physiol; 2019 Oct; 317(4):F1034-F1046. PubMed ID: 31411076
[TBL] [Abstract][Full Text] [Related]
7. Insights into serum metabolic biomarkers for early detection of incident diabetic kidney disease in Chinese patients with type 2 diabetes by random forest.
Jiang JJ; Sham TT; Gu XF; Chan CO; Dong NP; Lim WH; Song GF; Li SM; Mok DK; Ge N
Aging (Albany NY); 2024 Feb; 16(4):3420-3530. PubMed ID: 38349886
[TBL] [Abstract][Full Text] [Related]
8. Integration of metabolomics and peptidomics reveals distinct molecular landscape of human diabetic kidney disease.
Jiang X; Liu X; Qu X; Zhu P; Wo F; Xu X; Jin J; He Q; Wu J
Theranostics; 2023; 13(10):3188-3203. PubMed ID: 37351171
[TBL] [Abstract][Full Text] [Related]
9. Metabolomics reveal mitochondrial and fatty acid metabolism disorders that contribute to the development of DKD in T2DM patients.
Li L; Wang C; Yang H; Liu S; Lu Y; Fu P; Liu J
Mol Biosyst; 2017 Oct; 13(11):2392-2400. PubMed ID: 28956034
[TBL] [Abstract][Full Text] [Related]
10. Identification of Potential Serum Metabolic Biomarkers of Diabetic Kidney Disease: A Widely Targeted Metabolomics Study.
Zhang H; Zuo JJ; Dong SS; Lan Y; Wu CW; Mao GY; Zheng C
J Diabetes Res; 2020; 2020():3049098. PubMed ID: 32190695
[TBL] [Abstract][Full Text] [Related]
11. Clinical metabolomics characteristics of diabetic kidney disease: A meta-analysis of 1875 cases with diabetic kidney disease and 4503 controls.
Yuan Y; Huang L; Yu L; Yan X; Chen S; Bi C; He J; Zhao Y; Yang L; Ning L; Jin H; Yang R; Li Y
Diabetes Metab Res Rev; 2024 Mar; 40(3):e3789. PubMed ID: 38501707
[TBL] [Abstract][Full Text] [Related]
12. Impaired Amino Acid Metabolism and Its Correlation with Diabetic Kidney Disease Progression in Type 2 Diabetes Mellitus.
Zhu H; Bai M; Xie X; Wang J; Weng C; Dai H; Chen J; Han F; Lin W
Nutrients; 2022 Aug; 14(16):. PubMed ID: 36014850
[TBL] [Abstract][Full Text] [Related]
13. Development and internal validation of machine learning algorithms for end-stage renal disease risk prediction model of people with type 2 diabetes mellitus and diabetic kidney disease.
Zou Y; Zhao L; Zhang J; Wang Y; Wu Y; Ren H; Wang T; Zhang R; Wang J; Zhao Y; Qin C; Xu H; Li L; Chai Z; Cooper ME; Tong N; Liu F
Ren Fail; 2022 Dec; 44(1):562-570. PubMed ID: 35373711
[TBL] [Abstract][Full Text] [Related]
14. The Accumulation of Gut Microbiome-derived Indoxyl Sulfate and P-Cresyl Sulfate in Patients With End-stage Renal Disease.
Lin X; Liang W; Li L; Xiong Q; He S; Zhao J; Guo X; Xiang S; Zhang P; Wang H; Ying C; Yao Y; Zuo X
J Ren Nutr; 2022 Sep; 32(5):578-586. PubMed ID: 34736844
[TBL] [Abstract][Full Text] [Related]
15. Gut microbiota and its metabolites - molecular mechanisms and management strategies in diabetic kidney disease.
Mao ZH; Gao ZX; Liu DW; Liu ZS; Wu P
Front Immunol; 2023; 14():1124704. PubMed ID: 36742307
[TBL] [Abstract][Full Text] [Related]
16. Current updates on metabolites and its interlinked pathways as biomarkers for diabetic kidney disease: A systematic review.
Das S; Devi Rajeswari V; Venkatraman G; Elumalai R; Dhanasekaran S; Ramanathan G
Transl Res; 2024 Mar; 265():71-87. PubMed ID: 37952771
[TBL] [Abstract][Full Text] [Related]
17. Metabolomic biomarkers in diabetic kidney diseases--A systematic review.
Zhang Y; Zhang S; Wang G
J Diabetes Complications; 2015; 29(8):1345-51. PubMed ID: 26253264
[TBL] [Abstract][Full Text] [Related]
18. Quantitative analysis of amino acids and acylcarnitines combined with untargeted metabolomics using ultra-high performance liquid chromatography and quadrupole time-of-flight mass spectrometry.
Roy C; Tremblay PY; Bienvenu JF; Ayotte P
J Chromatogr B Analyt Technol Biomed Life Sci; 2016 Aug; 1027():40-9. PubMed ID: 27240302
[TBL] [Abstract][Full Text] [Related]
19. Metabolomic analysis of uremic toxins by liquid chromatography/electrospray ionization-tandem mass spectrometry.
Kikuchi K; Itoh Y; Tateoka R; Ezawa A; Murakami K; Niwa T
J Chromatogr B Analyt Technol Biomed Life Sci; 2010 Jun; 878(20):1662-8. PubMed ID: 20036201
[TBL] [Abstract][Full Text] [Related]
20. Urine and plasma metabolites predict the development of diabetic nephropathy in individuals with Type 2 diabetes mellitus.
Pena MJ; Lambers Heerspink HJ; Hellemons ME; Friedrich T; Dallmann G; Lajer M; Bakker SJ; Gansevoort RT; Rossing P; de Zeeuw D; Roscioni SS
Diabet Med; 2014 Sep; 31(9):1138-47. PubMed ID: 24661264
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
